1.Patients who have previously had a score of 6 or 7 on the 9-point ordinal scale. <br/ >2.Inability to swallow capsules (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug) <br/ >3.History of the following cardiac conditions: <br/ >a)Myocardial infarction within 3 months prior to the first dose <br/ >b)Unstable angina <br/ >c)History of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia [â?¤55 bpm]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT.Patients with an implantable cardioverter defibrillator device in place, will be allowed to enrol. Atrial fibrillation will not be a reason for exclusion. <br/ >4.Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) >470 msec. In the presence of a cardiac pacemaker, QTcF will need to be calculated from an ECG which has been recorded during a period where ventricular (QRS) complexes without pacing are present. If no unpaced ventricular complexes are present to allow calculation of QTcF, the patient should not be enrolled in this protocol <br/ >5.Clinically significant hypokalaemia: Individuals who do not meet this criterion may be rescreened once, after correction of 6.Therapeutic anticoagulation with vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. <br/ >7.Previous bowel resection that would interfere with drug absorption. <br/ >8.Any patient whose interests are not best served by study participation, as determined by a senior attending clinician. <br/ >9.Alanine aminotransferase/aspartate aminotransferase >5 Ã? the upper limit of normal electrolyte abnormality. <br/ >10.Current treatment (or planned initiation of treatment during the first 15 days of the study) for human immunodeficiency virus (HIV) or tuberculosis (TB). <br/ >11.Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory. <br/ >12.Stage 4 severe chronic kidney disease. <br/ >13.Anticipated transfer to another hospital that is not a study centre within 72 hours. <br/ >14.Allergy to any study treatment. <br/ >15.Experimental off-label usage of medicinal products as treatments for COVID-19 (except where the product has either been given a positive opinion under the Early Access to Medicines Scheme [EAMS] or is a SARS-CoV-2 vaccine) at the time of enrolment. <br/ >16.Patients participating in another clinical study of an investigational medicinal product. <br/ >17.Current or planned treatment for tuberculosis. <br/ >

1.Patients who have previously had a score of 6 or 7 on the 9-point ordinal scale. <br/ >2.Inability to swallow capsules (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug) <br/ >3.History of the following cardiac conditions: <br/ >a)Myocardial infarction within 3 months prior to the first dose <br/ >b)Unstable angina <br/ >c)History of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia [â?¤55 bpm]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT.Patients with an implantable cardioverter defibrillator device in place, will be allowed to enrol. Atrial fibrillation will not be a reason for exclusion. <br/ >4.Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) >470 msec. In the presence of a cardiac pacemaker, QTcF will need to be calculated from an ECG which has been recorded during a period where ventricular (QRS) complexes without pacing are present. If no unpaced ventricular complexes are present to allow calculation of QTcF, the patient should not be enrolled in this protocol <br/ >5.Clinically significant hypokalaemia: Individuals who do not meet this criterion may be rescreened once, after correction of 6.Therapeutic anticoagulation with vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. <br/ >7.Previous bowel resection that would interfere with drug absorption. <br/ >8.Any patient whose interests are not best served by study participation, as determined by a senior attending clinician. <br/ >9.Alanine aminotransferase/aspartate aminotransferase >5 Ã? the upper limit of normal electrolyte abnormality. <br/ >10.Current treatment (or planned initiation of treatment during the first 15 days of the study) for human immunodeficiency virus (HIV) or tuberculosis (TB). <br/ >11.Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory. <br/ >12.Stage 4 severe chronic kidney disease. <br/ >13.Anticipated transfer to another hospital that is not a study centre within 72 hours. <br/ >14.Allergy to any study treatment. <br/ >15.Experimental off-label usage of medicinal products as treatments for COVID-19 (except where the product has either been given a positive opinion under the Early Access to Medicines Scheme [EAMS] or is a SARS-CoV-2 vaccine) at the time of enrolment. <br/ >16.Patients participating in another clinical study of an investigational medicinal product. <br/ >17.Current or planned treatment for tuberculosis. <br/ >

N/A

N/A

1.Patients who have previously had a score of 6 or 7 on the 9-point ordinal scale. <br/ >2.Inability to swallow capsules (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug) <br/ >3.History of the following cardiac conditions: <br/ >a)Myocardial infarction within 3 months prior to the first dose <br/ >b)Unstable angina <br/ >c)History of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia [â?¤55 bpm]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT.Patients with an implantable cardioverter defibrillator device in place, will be allowed to enrol. Atrial fibrillation will not be a reason for exclusion. <br/ >4.Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) >470 msec. In the presence of a cardiac pacemaker, QTcF will need to be calculated from an ECG which has been recorded during a period where ventricular (QRS) complexes without pacing are present. If no unpaced ventricular complexes are present to allow calculation of QTcF, the patient should not be enrolled in this protocol <br/ >5.Clinically significant hypokalaemia: Individuals who do not meet this criterion may be rescreened once, after correction of 6.Therapeutic anticoagulation with vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. <br/ >7.Previous bowel resection that would interfere with drug absorption. <br/ >8.Any patient whose interests are not best served by study participation, as determined by a senior attending clinician. <br/ >9.Alanine aminotransferase/aspartate aminotransferase >5 Ã? the upper limit of normal electrolyte abnormality. <br/ >10.Current treatment (or planned initiation of treatment during the first 15 days of the study) for human immunodeficiency virus (HIV) or tuberculosis (TB). <br/ >11.Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory. <br/ >12.Stage 4 severe chronic kidney disease. <br/ >13.Anticipated transfer to another hospital that is not a study centre within 72 hours. <br/ >14.Allergy to any study treatment. <br/ >15.Experimental off-label usage of medicinal products as treatments for COVID-19 (except where the product has either been given a positive opinion under the Early Access to Medicines Scheme [EAMS] or is a SARS-CoV-2 vaccine) at the time of enrolment. <br/ >16.Patients participating in another clinical study of an investigational medicinal product. <br/ >17.Current or planned treatment for tuberculosis. <br/ >

1.Patients who have previously had a score of 6 or 7 on the 9-point ordinal scale. <br/ >2.Inability to swallow capsules (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug) <br/ >3.History of the following cardiac conditions: <br/ >a)Myocardial infarction within 3 months prior to the first dose <br/ >b)Unstable angina <br/ >c)History of clinically significant dysrhythmias (long QT features on ECG, sustained bradycardia [â?¤55 bpm]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT.Patients with an implantable cardioverter defibrillator device in place, will be allowed to enrol. Atrial fibrillation will not be a reason for exclusion. <br/ >4.Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) >470 msec. In the presence of a cardiac pacemaker, QTcF will need to be calculated from an ECG which has been recorded during a period where ventricular (QRS) complexes without pacing are present. If no unpaced ventricular complexes are present to allow calculation of QTcF, the patient should not be enrolled in this protocol <br/ >5.Clinically significant hypokalaemia: Individuals who do not meet this criterion may be rescreened once, after correction of 6.Therapeutic anticoagulation with vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. <br/ >7.Previous bowel resection that would interfere with drug absorption. <br/ >8.Any patient whose interests are not best served by study participation, as determined by a senior attending clinician. <br/ >9.Alanine aminotransferase/aspartate aminotransferase >5 Ã? the upper limit of normal electrolyte abnormality. <br/ >10.Current treatment (or planned initiation of treatment during the first 15 days of the study) for human immunodeficiency virus (HIV) or tuberculosis (TB). <br/ >11.Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory. <br/ >12.Stage 4 severe chronic kidney disease. <br/ >13.Anticipated transfer to another hospital that is not a study centre within 72 hours. <br/ >14.Allergy to any study treatment. <br/ >15.Experimental off-label usage of medicinal products as treatments for COVID-19 (except where the product has either been given a positive opinion under the Early Access to Medicines Scheme [EAMS] or is a SARS-CoV-2 vaccine) at the time of enrolment. <br/ >16.Patients participating in another clinical study of an investigational medicinal product. <br/ >17.Current or planned treatment for tuberculosis. <br/ >